---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-245484"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2026-05-28T21:06:28+00:00"
generated_at: "2026-05-28T21:15:21.054418+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director

## Summary
- Zachary Roberts, M.D., Ph.D., currently EVP R&D and CMO, named President and CEO effective July 1, 2026.
- Dr. Roberts receives $680k base salary, 60% target bonus, options for 476,190 shares, and 134,530 RSUs.
- Outgoing CEO David Chang, M.D., Ph.D. will remain on the Board as a non-employee director after June 30, 2026.
- Dr. Chang eligible for severance benefits under Allogene's Change in Control and Severance Benefit Plan.

## SEC filing metadata
- accession: 0001193125-26-245484
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2026-05-28T21:06:28+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/d65280d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-245484
- JSON: https://secwatch.observer/filing/0001193125-26-245484.json
- Plain text: https://secwatch.observer/filing/0001193125-26-245484.txt

## Source-grounded claims
- claim_id: 18865b97bf
  claim: Zachary Roberts was appointed as President and Chief Executive Officer at Allogene Therapeutics, Inc..
  evidence_excerpt: the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm
- claim_id: 1bad2c1b70
  claim: David Chang was appointed as non-employee director at Allogene Therapeutics, Inc..
  evidence_excerpt: Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm
- claim_id: 251b68b71b
  claim: David Chang resigned as President and Chief Executive Officer at Allogene Therapeutics, Inc..
  evidence_excerpt: Dr. Chang’s last day of service in these positions will be June 30, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm
- claim_id: 43fe04daa5
  claim: Zachary Roberts changed role as Chief Medical Officer (interim) at Allogene Therapeutics, Inc..
  evidence_excerpt: Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm
- claim_id: d2e8883ed6
  claim: Zachary Roberts was appointed as Class I director at Allogene Therapeutics, Inc..
  evidence_excerpt: Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.